.png){kind=icon}
.png){kind=icon}
Return
Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives
.png){kind=icon}
OA
AI
M
N
A
K
S
DOI：10.1080/13510002.2026.2677396.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Alzheimer's disease (AD) is a major global neurodegenerative disorder associated with high morbidity and mortality, yet current treatments remain largely symptomatic and ineffective in halting neurodegeneration. Growing evidence links oxidative stress potentially being an early event in AD progression. Consequently, therapeutic strategies targeting oxidative stress–mediated cellular damage are increasingly attractive. This review summarizes clinical evidence of oxidative stress biomarkers in AD and examines the neuroprotective mechanisms of flavonoids against oxidative stress in vivo, together with current clinical findings. Despite inconsistencies among studies due to variations in detection methods, a consistent trend of elevated oxidative stress in AD is evident, correlating with disease severity. Although in vivo studies have demonstrated that flavonoids restore antioxidant defences and suppress neuroinflammation, convincing clinical evidence of their efficacy in AD patients remains limited. Overall, these findings emphasize oxidative stress as a therapeutic target requiring further validation efforts.
Keywords:
Alzheimer's disease
oxidative stress
biomarkers
flavonoid
antioxidant
lipid peroxidation
microgliosis
Journal
IF:
7.4
Papers:
1.3K
Citations:
2.4K
Organization
Cited Papers